openPR Logo
Press release

Hemorrhoids Market Projected to Reach USD 3.7 Billion by 2034

08-26-2025 12:03 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Hemorrhoids

Hemorrhoids

Hemorrhoids, also known as piles, are swollen and inflamed veins in the anus that cause discomfort, bleeding, pain, and itching. They are one of the most common anorectal conditions, affecting millions of people worldwide across all age groups. Risk factors include sedentary lifestyle, obesity, chronic constipation, pregnancy, and aging populations.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71143

Although often underreported due to stigma, the rising prevalence of hemorrhoids is driving significant demand for effective treatments. From over-the-counter (OTC) creams and suppositories to minimally invasive surgical techniques, the hemorrhoids market is evolving with innovations in patient care, pain management, and surgical device technologies. Increasing awareness, improving healthcare access, and higher emphasis on gastrointestinal well-being are expected to push the market upward over the next decade.

Market Overview
• Market Size (2024): USD 2.1 billion
• Forecast (2034): USD 3.7 billion
• CAGR (2025-2034): 5.9%

The hemorrhoids market is projected to grow steadily, supported by rising diagnosis rates, expansion of self-medication through OTC products, and advancements in surgical technologies such as stapled hemorrhoidopexy and laser treatments. However, social stigma, high recurrence rates, and reliance on low-cost generics remain ongoing challenges.

Key Highlights:
• Increasing sedentary lifestyles and chronic constipation driving prevalence.
• OTC products dominate, but minimally invasive surgical options are expanding.
• Growing geriatric and pregnant populations contributing to demand.
• Rising adoption of laser and Doppler-guided hemorrhoid procedures.

Segmentation Analysis
By Product Type:
• Over-the-Counter (OTC) Treatments
o Creams & Ointments
o Suppositories
o Oral Medications
• Prescription Drugs
• Minimally Invasive Surgical Procedures
o Rubber Band Ligation
o Sclerotherapy
o Infrared Coagulation
o Stapled Hemorrhoidopexy
o Laser Treatment
• Surgical Devices & Instruments

By Platform:
• Pharmaceuticals (OTC & prescription)
• Medical Devices (surgical & minimally invasive systems)

By Technology:
• Conventional Surgical Techniques
• Minimally Invasive Procedures
• Laser & Doppler-Guided Innovations

By End Use:
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics
• Retail & Online Pharmacies

By Application:
• Internal Hemorrhoids
• External Hemorrhoids
• Mixed Hemorrhoids

Segmentation Summary:
OTC products dominate the market due to ease of access and affordability, while minimally invasive surgical options are gaining traction for patients with advanced or recurring hemorrhoids. Hospitals and specialty clinics remain the leading end-use segments, but online pharmacies are emerging as a fast-growing distribution channel for OTC formulations.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71143/hemorrhoids-market

Regional Analysis
North America
• Largest market with ~38% share in 2024.
• High prevalence due to sedentary lifestyles and widespread adoption of OTC treatments.
• Strong demand for advanced surgical techniques in the U.S. and Canada.
Europe
• Accounts for ~29% share.
• Germany, UK, and France lead with strong adoption of laser hemorrhoidectomy.
• Expanding reimbursement frameworks support treatment accessibility.
Asia-Pacific
• Fastest-growing region with CAGR of ~7%.
• Large patient pool in China, India, and Japan.
• Growing medical tourism and rapid adoption of minimally invasive surgeries.
Middle East & Africa
• Smaller market, limited by awareness and access.
• Gradual expansion of specialty clinics improving uptake.
Latin America
• Brazil and Mexico drive growth with rising diagnosis rates and wider adoption of OTC medications.
Regional Summary:
North America and Europe dominate in terms of market share due to established healthcare systems and high adoption of surgical procedures, while Asia-Pacific is set to record the fastest growth thanks to its vast patient pool and improving healthcare infrastructure.

Market Dynamics
Key Growth Drivers:
• Rising prevalence of constipation, obesity, and sedentary lifestyles.
• Growing acceptance and diagnosis of hemorrhoid-related conditions.
• Expanding OTC segment with easy consumer access.
• Advances in minimally invasive surgical procedures.
• Increasing geriatric and pregnant populations.

Key Challenges:
• High recurrence rates after initial treatment.
• Social stigma leading to underreporting and delayed diagnosis.
• Competition from low-cost generic OTC medications.
• Limited patient compliance with lifestyle modifications.

Latest Trends:
• Rapid adoption of laser and Doppler-guided surgical procedures.
• Growth of online pharmacies for OTC hemorrhoid products.
• Integration of digital health platforms for symptom tracking.
• Strategic partnerships between device makers and hospitals for training and adoption.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71143

Competitor Analysis
Major Players in the Market:
• Johnson & Johnson (Ethicon)
• Medtronic plc
• Boston Scientific Corporation
• Bayer AG
• Pfizer Inc.
• Cipla Ltd.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Dr. Reddy's Laboratories
• Teva Pharmaceutical Industries Ltd.

Competitive Summary:
The hemorrhoids market is moderately fragmented. Pharmaceutical companies such as Bayer, Sanofi, and Cipla dominate the OTC treatment space, while medical device leaders like Johnson & Johnson, Medtronic, and Boston Scientific are advancing minimally invasive and surgical systems. Growing competition from generics and regional players is increasing affordability, particularly in Asia-Pacific and Latin America.

Conclusion
The Hemorrhoids Market, valued at USD 2.1 billion in 2024, is projected to reach USD 3.7 billion by 2034, growing at a CAGR of 5.9%. Rising prevalence, greater awareness, and expanding access to both OTC and advanced surgical options will shape steady growth.

Key Takeaways:
• OTC medications remain the dominant segment, but surgical innovations are expanding rapidly.
• North America and Europe lead today, while Asia-Pacific shows the fastest growth.
• Social stigma and recurrence remain challenges but also create demand for minimally invasive solutions.
• Digital health, online pharmacies, and advanced surgical devices are transforming patient care.
Over the next decade, the hemorrhoids market will evolve toward patient-centric, minimally invasive, and accessible solutions, positioning it as a key growth area within gastrointestinal healthcare.

This report is also available in the following languages : Japanese (痔の市場), Korean (치질 시장), Chinese (痔疮市场), French (Marché des hémorroïdes), German (Hämorrhoidenmarkt), and Italian (Mercato delle emorroidi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71143/hemorrhoids-market#request-a-sample

Our More Reports:

Autoimmune Psychosis Market
https://exactitudeconsultancy.com/reports/71359/autoimmune-psychosis-market

Antibody-Mediated Graft Rejection Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71361/antibody-mediated-graft-rejection-patient-pool-analysis-market

Irritable Bowel Syndrome (IBS) Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71363/irritable-bowel-syndrome-ibs-patient-pool-analysis-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemorrhoids Market Projected to Reach USD 3.7 Billion by 2034 here

News-ID: 4159761 • Views:

More Releases from Exactitude Consultancy

Liver Fibrosis Market Massive Growth opportunity Ahead
Liver Fibrosis Market Massive Growth opportunity Ahead
Introduction Liver fibrosis, defined by the excessive accumulation of scar tissue in response to chronic liver injury, is increasingly recognized as a global public health challenge. The growing incidence of non-alcoholic fatty liver disease (NAFLD), hepatitis infections, and alcohol-related liver damage has intensified the need for effective detection and treatment strategies. As the condition progresses, it can lead to cirrhosis or hepatocellular carcinoma-both associated with high public health and economic burdens. In
Gastritis Market to Grow to USD 11.2 Billion by 2034, Registering a 5.6% CAGR
Gastritis Market to Grow to USD 11.2 Billion by 2034, Registering a 5.6% CAGR
Gastritis is the inflammation of the stomach lining, often caused by infection with Helicobacter pylori, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), excessive alcohol intake, or autoimmune conditions. It can manifest as acute or chronic and, if untreated, may progress to ulcers or increase the risk of gastric cancer. With lifestyle changes, increasing medication use, and rising prevalence of GI disorders, gastritis has become one of the most common conditions
Chronic Lymphocytic Leukemia Market Expected to Reach USD 17.2 Billion by 2034
Chronic Lymphocytic Leukemia Market Expected to Reach USD 17.2 Billion by 2034
Chronic Lymphocytic Leukemia (CLL) is the most common type of adult leukemia in Western countries, characterized by the slow accumulation of dysfunctional B-lymphocytes in the blood, bone marrow, and lymphoid tissues. While often indolent in its early stages, CLL can progress to life-threatening complications, necessitating advanced treatments such as targeted therapies, chemotherapy, and immunotherapy. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71167 The market for CLL is growing steadily, driven
Functional Constipation Market Poised to Hit USD 13.6 Billion by 2034
Functional Constipation Market Poised to Hit USD 13.6 Billion by 2034
Functional constipation (FC) is a common gastrointestinal disorder characterized by infrequent bowel movements, hard stools, and difficulty during defecation, without any underlying structural or biochemical cause. It affects millions of people worldwide, significantly impacting quality of life and often leading to increased healthcare visits. Unlike secondary constipation, which results from medication or disease, functional constipation is chronic and influenced by diet, lifestyle, and psychosocial factors. Download Full PDF Sample Copy of

All 5 Releases


More Releases for OTC

Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain adidas AG officers and
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services. The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market. The
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to